Karnataka drugs control department has issued a circular to stop the production and sales of Rimonabant. This order comes well before the drugs controller general of India circular to all the state departments.
"Going by the reports on the ban of Rimonabant across the world, we have taken a decision to ensure that this product is not available in the state. We are giving the pharmacy outlets across the state a month's time to withdraw and return all samples to the manufacturers," Dr BR Jugashetty, Drugs Controller, Government of Karnataka told.
The anti-obesity market in India is valued at Rs 75 crore. Leading players in the country include Sun Pharma, Cadila, Cipla, Glenmark, Torrent, Dr Reddy's, Ranbaxy and Intas.
